These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31477413)

  • 1. The Future of Immunotherapy in the Treatment of Cancer.
    Kottschade LA
    Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
    Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving nursing science and practice in cancer survivorship.
    Haylock PJ
    Semin Oncol Nurs; 2015 Feb; 31(1):3-12. PubMed ID: 25636391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provision of survivorship care for patients with haematological malignancy at completion of treatment: A cancer nursing practice survey study.
    Wallace A; Downs E; Gates P; Thomas A; Yates P; Chan RJ
    Eur J Oncol Nurs; 2015 Oct; 19(5):516-22. PubMed ID: 25795159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
    Mistry H; Forbes SG; Fowler N
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital.
    Rasor B; Henderson R; Chan K
    J Oncol Pharm Pract; 2020 Jan; 26(1):60-66. PubMed ID: 30924739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncology nurses' knowledge of survivorship care planning: the need for education.
    Lester JL; Wessels AL; Jung Y
    Oncol Nurs Forum; 2014 Mar; 41(2):E35-43. PubMed ID: 24578084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Prevention in the Survivorship Setting.
    Lewis-Patterson P; Palos GR; Dains J; Jackson TL
    Semin Oncol Nurs; 2016 Aug; 32(3):291-305. PubMed ID: 27539283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on New Therapies With Immune Checkpoint Inhibitors.
    Peterson JJ; Steele-Moses SK
    Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oncologic nursing in the year 2000; a preview].
    Sensmeyer A
    Krankenpflege (Frankf); 1990; 44(7-8):390-3. PubMed ID: 2122063
    [No Abstract]   [Full Text] [Related]  

  • 14. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer and the Immune System: The History and Background of Immunotherapy.
    Abbott M; Ustoyev Y
    Semin Oncol Nurs; 2019 Oct; 35(5):150923. PubMed ID: 31526550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to mitigate the toxicity of cancer therapeutics.
    Kahn AM; Blenman KRM; Sonis ST; Lustberg MB
    Adv Cancer Res; 2022; 155():215-244. PubMed ID: 35779875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view].
    Cisarovsky C; Kraege V; Obeid M; Garnier A
    Rev Med Suisse; 2020 Nov; 16(716):2264-2270. PubMed ID: 33237644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.